Global Measles and Rubella Laboratory Network Support for Elimination Goals, 2010–2015
| Autor: | Makoto Takeda, Charles Byabamazima, James L. Goodson, Sirima Pattamadilok, Marta Gacic-Dobo, Gloria Rey, Hinda Ahmed, Paul A. Rota, Yan Zhang, Myriam Ben Mamou, Joseph P. Icenogle, Kevin E. Brown, Peter M. Strebel, Mick N. Mulders, Annick Dosseh |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Pathology Health (social science) Epidemiology Health Toxicology and Mutagenesis Vital signs Global Health World Health Organization Rubella Measles 03 medical and health sciences 0302 clinical medicine Health Information Management Environmental health Global health Humans Medicine 030212 general & internal medicine Disease Eradication Congenital rubella syndrome business.industry Public health General Medicine medicine.disease 030104 developmental biology Action plan Laboratories business Goals |
| Zdroj: | MMWR. Morbidity and Mortality Weekly Report. 65:438-442 |
| ISSN: | 1545-861X 0149-2195 2012-2020 |
| Popis: | In 2012, the World Health Assembly endorsed the Global Vaccine Action Plan (GVAP)* with the objective to eliminate measles and rubella in five World Health Organization (WHO) regions by 2020. In September 2013, countries in all six WHO regions had established measles elimination goals, and additional goals for elimination of rubella and congenital rubella syndrome were established in three regions (1). Capacity for surveillance, including laboratory confirmation, is fundamental to monitoring and verifying elimination. The 2012-2020 Global Measles and Rubella Strategic Plan of the Measles and Rubella Initiative(†) calls for effective case-based surveillance with laboratory testing for case confirmation (2). In 2000, the WHO Global Measles and Rubella Laboratory Network (GMRLN) was established to provide high quality laboratory support for surveillance (3). The GMRLN is the largest globally coordinated laboratory network, with 703 laboratories supporting surveillance in 191 countries. During 2010-2015, 742,187 serum specimens were tested, and 27,832 viral sequences were reported globally. Expansion of the capacity of the GMRLN will support measles and rubella elimination efforts as well as surveillance for other vaccine-preventable diseases (VPDs), including rotavirus, and for emerging pathogens of public health concern. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|